Nexium Dominates No.1, 2 Positions in Both GP, HP Markets in September Prior to Lifting of Ban on Long-Term Prescription: RepTrack Survey

According to the RepTrack Survey by Anterio Inc., which conducts research on the recollections of doctors on drug detailing activities, the proton pump inhibitor (PPI) Nexium (esomeprazole) copromoted by Daiichi Sankyo and AstraZeneca K.K. (AZ) dominated the No.1 and 2...read more